GSK completes Sirtris acquisition
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline acquires Sirtris Pharmaceuticals for approximately $720 million through a cash tender offer and merger of $22.50 per share, the firms state June 6. The buy significantly enhances GSK's "metabolic, neurology, immunology and inflammation research efforts by establishing a presence in the field of sirtuins, a recently discovered class of enzymes that is believed to be involved in the ageing process," according to the London-based firm. Sirtris' lead compound is resveratrol based (1"The Tan Sheet" April 28, 2008, In Brief)....